The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2022

Filed:

Jan. 13, 2017
Applicant:

The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US);

Inventors:

Hildegund C. J. Ertl, Villanova, PA (US);

Ying Zhang, Boston, MA (US);

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/192 (2006.01); A61K 35/17 (2015.01); A61K 35/26 (2015.01); A61K 31/216 (2006.01); A61K 31/195 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); A61K 39/00 (2006.01); C12N 5/0781 (2010.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); A61K 31/7056 (2006.01); C12N 5/0783 (2010.01);
U.S. Cl.
CPC ...
A61K 31/216 (2013.01); A61K 9/0053 (2013.01); A61K 31/192 (2013.01); A61K 31/195 (2013.01); A61K 31/7056 (2013.01); A61K 35/17 (2013.01); A61K 35/26 (2013.01); A61K 39/0011 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C12N 5/0635 (2013.01); C12N 5/0636 (2013.01); G01N 33/574 (2013.01); A61K 2039/53 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55516 (2013.01); C12N 2510/00 (2013.01); C12N 2710/10043 (2013.01);
Abstract

Methods for treating cancer are disclosed which comprise administering to a subject T cells which have been pretreated ex vivo or in vitro with a fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production. Still other methods comprise co-administering to a subject having a cancer characterized by a solid tumor (a) an immunotherapeutic composition targeting an antigen or ligand on the tumor cell; and (b) a compound or reagent that promotes the use of fatty acid catabolism by tumor antigen-specific T cells in the tumor microenvironment and/or T cells pretreated ex vivo with the fatty acid catabolism promoter to condition the T cell to use fatty acids rather than glucose for energy production for adoptive cell transfer. Both methods may also employ co-administration of a checkpoint inhibitor.


Find Patent Forward Citations

Loading…